Tuberculosis is the second leading cause of morbidity and mortality worldwide due to an infectious disease. Development of a new tuberculosis (TB) vaccine would be facilitated by a better understanding of the mechanisms of protection induced by the current TB vaccine, Mycobacterium bovis BCG. Recombinant guinea pig (rgp)CCL5 and anti-rgpCCL5 were developed and characterized. The biological activity of rgpCCL5 was determined in a chemotaxis assay using T lymphocytes and pleural exudate cells. The specificity of rabbit anti-rgpCCL5 polyclonal antibody was confirmed by Western blot. RgpCCL5 was used to stimulate alveolar and peritoneal macrophages in vitro. and cytokine/chemokine gene expression was evaluated using real-time PCR. RgpCCL5 s...
Tuberculosis (TB) continues to ravage humanity, causing 2 million deaths per year. A vaccine against...
Background The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Guréin (BCG) vacci...
Background: The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Gure´in (BCG) vacc...
Tuberculous pleurisy is a severe inflammatory response induced by Mycobacterium tuberculosis organis...
Background: Host resistance to pulmonary tuberculosis is associated with the induction of IFN-y secr...
The effect of Mycobacterium bovis BCG vaccination on interleukin-1 (IL-1) or regulated-upon-activat...
The Bacille Calmette–Guerin (BCG) vaccine offers partial protection against tuberculosis (TB). Vacci...
The Guinea pig has proven to be a reliable model for testing vaccine candidates against tuberculosis...
Tuberculosis is a major cause of death due to an infection in mankind. BCG vaccine protects against ...
Development of effective vaccine candidates against tuberculosis (TB) is currently the most importan...
Tuberculosis remains one of the most significant diseases of humans and animals. The only currently ...
Tuberculosis remains one of the most significant diseases of humans and animals. The only currently ...
Background: The variable efficacy (0-80%) of Mycobacterium bovis Bacille Calmette Gurein (BCG) vacci...
Tuberculosis, caused by the intracellular bacterium Mycobacterium tuberculosis (Mtb), is the second ...
AbstractThe lack of an efficient vaccine against tuberculosis is still one of the major problems thr...
Tuberculosis (TB) continues to ravage humanity, causing 2 million deaths per year. A vaccine against...
Background The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Guréin (BCG) vacci...
Background: The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Gure´in (BCG) vacc...
Tuberculous pleurisy is a severe inflammatory response induced by Mycobacterium tuberculosis organis...
Background: Host resistance to pulmonary tuberculosis is associated with the induction of IFN-y secr...
The effect of Mycobacterium bovis BCG vaccination on interleukin-1 (IL-1) or regulated-upon-activat...
The Bacille Calmette–Guerin (BCG) vaccine offers partial protection against tuberculosis (TB). Vacci...
The Guinea pig has proven to be a reliable model for testing vaccine candidates against tuberculosis...
Tuberculosis is a major cause of death due to an infection in mankind. BCG vaccine protects against ...
Development of effective vaccine candidates against tuberculosis (TB) is currently the most importan...
Tuberculosis remains one of the most significant diseases of humans and animals. The only currently ...
Tuberculosis remains one of the most significant diseases of humans and animals. The only currently ...
Background: The variable efficacy (0-80%) of Mycobacterium bovis Bacille Calmette Gurein (BCG) vacci...
Tuberculosis, caused by the intracellular bacterium Mycobacterium tuberculosis (Mtb), is the second ...
AbstractThe lack of an efficient vaccine against tuberculosis is still one of the major problems thr...
Tuberculosis (TB) continues to ravage humanity, causing 2 million deaths per year. A vaccine against...
Background The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Guréin (BCG) vacci...
Background: The variable efficacy (0–80%) of Mycobacterium bovis Bacille Calmette Gure´in (BCG) vacc...